IPO - Indaptus Therapeutics, Inc.

Form Type: POS AM

Filing Date: 2025-03-13

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225010137

Filing Summary: Indaptus Therapeutics, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 Registration Statement with the SEC on March 13, 2025. This amendment serves to update and supplement various details previously provided in its initial filing made on February 12, 2025, which was declared effective the following day. The Registration Statement covers the resale of up to 10,000,000 shares of common stock, with no additional securities registered under this amendment. Notably, common stock is managed by YA II PN, LTD., a Cayman Islands partnership, under a Standby Equity Purchase Agreement. Indaptus has committed to this offering, yet will not be selling any of its securities; instead, the proceeds will come from the stockholder sales. The issuer expects potential gross proceeds of up to $20 million based on sales to YA over a 36-month period, contingent on specific market conditions. The amendment outlines that as of March 12, 2025, the number of shares outstanding totalled 14,429,244, with 12,857,209 shares held by non-affiliates. If the shares offered are fully issued, this would represent about 41% of total shares. The document highlights ongoing clinical trials for Decoy20, an anti-cancer therapy in which patients have shown signs of stable disease after treatment. Additionally, it notes the recent financing events and compliance issues regarding Nasdaq's minimum bid price requirements, with specific deadlines for regaining compliance to avoid delisting.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006068

Filing Summary: Indaptus Therapeutics, Inc. filed a Form S-1 registration statement with the SEC to offer up to 10,000,000 shares of common stock. This offering is initiated under a Standby Equity Purchase Agreement with YA II PN, LTD. The company is not selling any securities and will not receive proceeds from the sale, but anticipates potential gross proceeds of up to $20 million from future sales of shares to YA over the next 36 months. Additionally, BA will receive 305,960 shares as compensation for its commitment to purchase shares, plus nearly 9.7 million shares of Advance Shares. The company's common stock is listed on the Nasdaq under the symbol 'INDP'. As of the last reported sale on February 11, 2025, the stock price was $0.8053. The offering hints at significant capital-raising efforts aimed at funding clinical trials and other operational needs, given their ongoing studies on Decoy20, an immunotherapy candidate currently in Phase 1 trials for solid tumors.

Document Link: View Document

Form Type: S-1

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000149315224051850

Filing Summary: Indaptus Therapeutics, Inc. has filed a registration statement on Form S-1 with the SEC for the proposed resale of 1,941,229 shares of its common stock by selling stockholders. These shares consist of 1,817,017 shares issuable upon exercise of investor warrants from a private placement in November 2024, and 124,212 shares issuable upon exercise of placement agent warrants. The company will not receive proceeds from the sale, but may receive proceeds from the exercise of warrants if exercised for cash. The last reported sale price on December 20, 2024, was $0.938 per share on the Nasdaq Capital Market under the symbol 'INDP'. The company emphasizes that the risk factors associated with investing in their securities have been outlined. They have never paid cash dividends and intend to retain future earnings for business use. Indaptus is described as a clinical biotechnology company focused on developing novel anti-cancer and anti-viral immunotherapy strategies, with upcoming clinical trials planned. The filing is part of regulatory compliance for their securities, and they have indicated an intent to initiate a Combination Study with BeiGene in 2025.

Document Link: View Document